Pre-Omicron effectiveness of COVID-19 vaccines against hospitalization and death across Canada

Published in Clinical Infectious Diseases, CITF-funded researchers Drs. Jeff Kwong (University of Toronto), Gaston de Serres (L’Institut national de santé publique du Québec), and Mel Krajden (University of British Columbia), found that two doses of mRNA or viral vector ChAdOx1 (AstraZeneca’s Vaxzevria or COVIDSHIELD) vaccines provided excellent protection against severe outcomes (hospitalization or death) from COVID-19 during the period before the emergence of the Omicron variant.